In a 1,880-person randomized trial of adults averaging 77.5 years who took statins for primary prevention and had at least two chronic conditions, stopping statins met the noninferiority threshold for a composite of nonfatal heart attack, nonfatal ischemic stroke, or death. Restricted mean event-free survival differed by only -2.0 weeks at 2 years, inside the -5.2-week margin. Raw events still favored continuation: 12.7% versus 9.2%.\n\nThe headline verdict hides a tension. The noninferiority margin was prespecified and clinically modest, yet the absolute event gap of 3.5 percentage points over roughly two years is not trivial, and the confidence interval (-3.7 to -0.3 weeks) excludes zero, meaning continuation showed a small measurable benefit even as discontinuation passed the test. Serious adverse events were also slightly higher after stopping (43.0% versus 39.8%), which argues against assuming deprescribing is automatically safer. The open-label design, a short two-year horizon, and a composite dominated by all-cause death all limit how far the result extends; statin benefit in primary prevention accrues slowly, so longer follow-up matters. It complements the earlier Japanese and French deprescribing signals and the SITE trial's more cautious direction. My read: confirmatory and useful, not a mandate to stop. For adults over 70 who are frail, have limited life expectancy, or suffer side effects or polypharmacy burden, a physician-guided discussion about stopping now has randomized support. For healthy, active older adults, continuing remains defensible.